← All protocols
Grade BCompoundedverifiedBioGate · GREENverifiedBioGate · GREEN

Post-Surgical Soft-Tissue Recovery

Accelerated tendon and connective-tissue recovery following elective orthopedic surgery

bpc-157 ↗tb-500 ↗
Protocol card

Eight audiences, one source of truth.

For clinicians

Dose & cycle

BPC-157 250 µg SC bid + TB-500 2 mg SC twice weekly

Cycle
4 weeks on / 2 weeks off
Duration
12 weeks (2 cycles)
For patients

Monitoring endpoints

  • ✓VAS pain score
  • ✓ROM (goniometric)
  • ✓CRP
  • ✓WHOOP recovery score 7-day rolling
Contraindications
  • ✕active malignancy
  • ✕uncontrolled diabetes
  • ✕pregnancy
Jurisdiction gates
US ✓
Compounded by 503A pharmacy
EU ✕
Special-needs prescription only
UK ✓
Unlicensed special order
AU ✓
TGA Schedule 4
Constituent peptides

Provenance, attestations, and structures.

BPC-157verifiedBioGate · GREEN
Structural preview · ESMFold-2 mockdeterministic per sequence
GEPPPGKPADDAGLV

Pentadecapeptide derived from human gastric juice; modulates VEGF and growth-hormone receptor expression in injured tissue.

TB-500 (Thymosin β-4 fragment)verifiedBioGate · GREEN
Structural preview · ESMFold-2 mockdeterministic per sequence
LKKTETQ

Active fragment of Thymosin β-4 (Tβ4); upregulates actin polymerization and endothelial cell migration.

IP economics

Cohort outcomes feed the royalty cascade.

Every revealed OEA from this protocol's cohorts updates the upstream IPNFT's outcome posterior. Holders receive pro-rata royalties from licensing, lab-fee escrow, and approved CRO contracts. Peptide MD does not custody the IPNFT; it indexes it through the Molecule registry.

IPNFT · Molecule IPNFT V2Solana
BPC-157
64fb58…2861fb
Royalty cascade
10.04%
Holders
73
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Supply provenance

COA-backed batches in the index.

BatchSupplierPurity (HPLC)Endotoxin (EU/mg)ManufacturedHash
TC-BPC-2026-0419-ATailored Compounding Pharmacy
US (FDA-registered 503A)
99.4%0.122026-04-19
ABP-TB-2026-0411-CAlpine BioPharma AG
Switzerland (Swissmedic)
99.6%0.082026-04-11
Citations

Every claim, traceable.

Grade B2013 · Curr Pharm Des

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease

Sikiric P et al.

PMID 23316008
Grade B2010 · J Orthop Res

Achilles tendon-to-bone reattachment: BPC 157 acceleration

Krivic A et al.

PMID 21030672
Grade A2010 · Angiogenesis

Thymosin beta-4 and angiogenesis: modes of action and therapeutic potential

Smart N et al.

PMID 18387880